Personal data for 108 individuals were collected during a 9-month period, including whole genome sequences; clinical tests, metabolomes, proteomes, and microbiomes at three time points; and daily activity tracking. Using all of these data, we generated a correlation network that revealed communities of related analytes associated with physiology and disease. Connectivity within analyte communities enabled the identification of known and candidate biomarkers (e.g., gamma-glutamyltyrosine was densely interconnected with clinical analytes for cardiometabolic disease). We calculated polygenic scores from genome-wide association studies (GWAS) for 127 traits and diseases, and used these to discover molecular correlates of polygenic risk (e.g., genetic risk for inflammatory bowel disease was negatively correlated with plasma cystine). Finally, behavioral coaching informed by personal data helped participants to improve clinical biomarkers. Our results show that measurement of personal data clouds over time can improve our understanding of health and disease, including early transitions to disease states.
A r t i c l e s
In order to understand the basis of wellness and disease, we and others have pursued a global and holistic approach termed 'systems medicine' 1 . The defining feature of systems medicine is the collection of diverse longitudinal data for each individual. These data sets can be used to unravel the complexity of human biology and disease by assessing both genetic and environmental determinants of health and their interactions. We refer to such data as personal, dense, dynamic data clouds: personal, because each data cloud is unique to an individual; dense, because of the high number of measurements; and dynamic, because we monitor longitudinally. The convergence of advances in systems medicine, big data analysis, individual measurement devices, and consumer-activated social networks has led to a vision of healthcare that is predictive, preventive, personalized, and participatory (P4) 2 , also known as 'precision medicine' . Personal, dense, dynamic data clouds are indispensable to realizing this vision 3 . The US healthcare system invests 97% of its resources on disease care 4 , with little attention to wellness and disease prevention. Here we investigate scientific wellness, which we define as a quantitative data-informed approach to maintaining and improving health and avoiding disease.
Several recent studies have illustrated the utility of multi-omic longitudinal data to look for signs of reversible early disease or disease risk factors in single individuals. The dynamics of human gut and salivary microbiota in response to travel abroad and enteric infection was characterized in two individuals using daily stool and saliva samples 5 . Daily multi-omic data collection from one individual over 14 months identified signatures of respiratory infection and the onset of type 2 diabetes 6 . Crohn's disease progression was tracked over many years in one individual using regular blood and stool measurements 7 . Each of these studies yielded insights into system dynamics even though they had only one or two participants.
We report the generation and analysis of personal, dense, dynamic data clouds for 108 individuals over the course of a 9-month study that we call the Pioneer 100 Wellness Project (P100). Our study included whole genome sequences; clinical tests, metabolomes, proteomes, and microbiomes at 3-month intervals; and frequent activity measurements (i.e., wearing a Fitbit). This study takes a different approach from previous studies, in that a broad set of assays were carried out less frequently in a (comparatively) large number of people. Furthermore, we identified 'actionable possibilities' for each individual to enhance her/his health. Risk factors that we observed in participants' clinical markers and genetics were used as a starting point to identify actionable possibilities for behavioral coaching.
We report the correlations among different data types and identify population-level changes in clinical markers. This project is the pilot for the 100,000 (100K) person wellness project that we proposed in 2014 (ref. 8 ). An increased scale of personal, dense, dynamic data clouds in future holds the potential to improve our understanding of scientific wellness and delineate early warning signs for human diseases.
RESULTS
The P100 study had four objectives. First, establish cost-efficient procedures for generating, storing, and analyzing multiple sources A wellness study of 108 individuals using personal, dense, dynamic data clouds A r t i c l e s of health data obtained over time from participants and analyzed in combination with genomic data. Second, develop and use analytic tools for integrating these diverse data sets and deriving actionable information from their observed interrelationships. Third, identify patterns within the health data that correlate with wellness, or transitions between wellness and disease. And fourth, learn how to best work with and present longitudinal health information to individuals by studying the reactions and feedback from participants as they are presented with actionable information.
Data collection 108 individuals (ages 21-89 + years; 59% males, 41% females; 89% of European descent; not recruited based on any specific phenotype) (Supplementary Table 1 ) participated in this study. In month 4, one participant reported to her coach that she had become pregnant and was withdrawn per protocol and informed consent. Health history and behavioral assessments were performed at the beginning of the study to establish a baseline for health coaching, including tobacco (4 reported users) and alcohol consumption (91 reported users). Each individual had their genome sequenced in full. Blood was collected in clinics every 3 months. Additionally, participants completed at-home collections of saliva, stool, and first morning void urine every 3 months. Stool and saliva samples were shipped directly to the vendor by the participant, while urine was given back to the study coordinators for distribution to the proper sample vendor (Fig. 1) . We called each of these three collection periods 'rounds' . For each participant in each round we carried out 218 clinical laboratory tests, measured up to 643 metabolites and 262 proteins, and measured the abundance of 4,616 operational taxonomic units in the gut microbiome using 16S rRNA sequencing. We used the whole genome sequence to calculate 127 polygenic scores for disease risks and quantitative traits based on previous studies selected from the National Human Genome Research Institute (NHGRI) GWAS catalog 9 . 
A r t i c l e s
Three common copy number variations were also included as genomic features, bringing the total to 130. All vendor measurements are listed in Supplementary Table 1 . Participants were asked to record weight, blood pressure, and resting heart rate weekly, and to track activity and sleep daily using a wearable device (Fitbit), although compliance with quantified self-tracking was relatively low.
Community structure in the correlation networks We built two age-and sex-adjusted correlation networks based on Spearman correlations across our cohort of individuals ( Fig. 2 and Supplementary Fig. 1 ). Cross-sectional correlations were calculated from mean measurements of analytes calculated using all three rounds (mean A is correlated with mean B across all individuals). Delta correlations were calculated on the change in analytes between rounds (the change in A between time points is correlated with the change in B across all individuals). In these networks, vertices (V) correspond to analytes, and an edge (E) exists between two vertices if and only if a significant (p adj < 0.05) correlation was observed after correction for multiple hypotheses 10 . The inter-omic cross-sectional correlation network contains 766 nodes and 3,470
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A r t i c l e s edges. The majority of edges involved a metabolite (3,309) or a clinical laboratory test (3, 366) , with an additional 20 edges involving the 130 genetic traits tested, 46 with microbiome taxa or diversity score, and 207 with quantified proteins. The inter-omic delta correlation network contained 822 nodes and 2,406 edges. 375 of the edges in the delta correlation network were also present in the cross-sectional network. The cross-sectional correlation network is provided in Supplementary We identified clusters of related measurements from the crosssectional inter-omic correlation network using community analysis, an unsupervised (i.e., using unlabeled data to find hidden structure) approach that iteratively prunes the network (removing the edges with the highest betweenness) to reveal densely interconnected subgraphs (communities) 11 . Seventy communities of at least two vertices (mean of 10.9 V and 34.9 E) were identified in the cross-sectional inter-omic network at the cutoff with maximum community modularity 12 (Supplementary Fig. 2) , and are fully visualized as an interactive graph in Cytoscape 13 ( Supplementary Dataset 1) . 70% of the edges in the cross-sectional network remained after community edge pruning. The communities often represented a cluster of physiologically related analytes, as described below.
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A r t i c l e s
The largest community (246 V; 1,645 E) contains many clinical analytes associated with cardiometabolic health, such as C-peptide, triglycerides, insulin, homeostatic risk assessment-insulin resistance (HOMA-IR), fasting glucose, high-density lipid (HDL) cholesterol, and small low-density lipid (LDL) particle number (Fig. 3) . The four most-connected clinical analytes by degree (the number of edges connecting a particular analyte) were C-peptide (degree 99), insulin (88), HOMA-IR (88), and triglycerides (75). The four most-connected proteins measured using targeted (i.e., selected reaction monitoring analysis) mass spectrometry or Olink proximity extension assays by degree are leptin (18), C-reactive protein (15) , fibroblast growth factor 21 (FGF21) (14) , and inhibin beta C chain (INHBC) (10) . Leptin and C-reactive protein are indicators for cardiovascular risk 14, 15 . FGF21 is positively correlated with the clinical analytes C-peptide (Spearman's ρ = 0.51; p adj = 3.1 × 10 −3 ), triglycerides (ρ = 0.50; p adj = 3.3 × 10 −3 ), HOMA-IR (ρ = 0.50; p adj = 3.6 × 10 −3 ), insulin (ρ = 0.47; p adj = 9.0 × 10 −3 ), and small LDL particle number (ρ = 0.42; p adj = 4.3 × 10 −2 ), and is a recently reported biomarker for cardiometabolic disorders 16 . INHBC, a member of the TGF-beta superfamily, is positively correlated with the clinical analytes triglycerides (ρ = 0.45; p adj = 3.0 × 10 −3 ), small LDL particle number (ρ = 0.43; p adj = 6.8 × 10 −3 ), C-peptide (ρ = 0.40; p adj = 1.8 × 10 −2 ), HOMA-IR (ρ = 0.38; p adj = 3.4 × 10 −2 ), and insulin (ρ = 0.38; p adj = 3.8 × 10 −2 ); it has not been reported to be a marker for cardiovascular risk and therefore represents an interesting candidate for follow-up. Serum amyloid P component (SAP) was positively correlated with LDL particle number (ρ = 0.39; p adj = 1.8 × 10 −2 ). SAP is a universal constituent of amyloid deposits observed in Alzheimer's disease 17 , and is associated with myocardial infarction 18 .
Total cholesterol and LDL cholesterol (LDL-C) segregate into a separate community from the cardiometabolic community (22 V; 48 E) with a broad array of plasma lipids (Fig. 4a) . Thyroid hormone lthyroxine is also present and is negatively correlated with total cholesterol levels (ρ = −0.44; p adj = 5.0 × 10 −4 ) as well as LDL cholesterol (ρ = −0.41; p adj = 2.1 × 10 −3 ). Hypothyroidism has long been recognized clinically as a cause of elevated cholesterol values 19 .
A community formed around plasma serotonin (18 V; 25 E) containing 12 proteins listed in Supplementary Table 6 , for which the most significant enrichment identified in a STRING ontology analysis 20 was platelet activation (p adj = 1.7 × 10 −3 ) (Fig. 4b) . Serotonin is known to induce platelet aggregation 21 ; accordingly, selective serotonin reuptake inhibitors (SSRIs) may protect against myocardial infarction 22 .
We identified several communities containing microbiome taxa, suggesting that there are specific microbiome-analyte relationships. Hydrocinnamate, l-urobilin, and 5-hydroxyhexanoate clustered with the bacterial class Mollicutes and family Christensenellaceae (8 V; 8 E). Another community emerged around the Verrucomicrobiaceae and Desulfovibrionaceae families and p-cresol-sulfate (7 V; 6 E). The Coriobacteriaceae and Mogibacteriaceae families were associated (12 V; 19 E) with phenylacetic acid, eicosadienoic acid, p-cresol-glucuronide, taurine, and phenylacetylglutamine. Phenylacetylglutamine, a known microbial metabolite 23 , was recently identified as a risk factor for mortality and cardiovascular disease in chronic kidney disease patients 24 . Finally, the bile acid cholate clusters with the Peptostreptococcaceae family (2 V; 1 E).
A community formed around microbiome α-diversity (8 V; 7 E), a measure of the number of operational taxonomic units observed and the evenness of their distributions; elevated diversity is generally thought to be associated with better health in part by ameliorating inflammation 25 . Microbiome α-diversity was negatively correlated with inflammatory and immune-related proteins, including interleukin-8 (IL-8), FMSrelated tyrosine kinase 3 (FLT3LG), and macrophage colony-stimulating factor 1 (CSF1) (Fig. 4c) . In contrast, β-nerve growth factor (NGF) was positively correlated with microbiome α-diversity. An analysis using STRING 20 on α-diversity community members revealed a significant enrichment in the KEGG pathway cytokine-cytokine receptor interaction (p adj = 1.1 × 10 −4 ); other pathway members have been implicated in the pathogenesis of inflammatory bowel disease 26 . 
Mining multi-omic communities for potential biomarkers One highly interconnected metabolite in the cardiometabolic community, gamma-glutamyltyrosine (degree 27), was significantly correlated with markers of cardiometabolic disease: glucose (ρ = 0.41; p adj = 1.6 × 10 −3 ), HOMA-IR (ρ = 0.38; p adj = 6.0 × 10 −3 ), and insulin (ρ = 0.36; p adj = 9.7 × 10 −3 ), as well as triglycerides (ρ = 0.41; p adj = 1.5 × 10 −3 ), small LDL particle number (ρ = 0.35; p adj = 1.5 × 10 −2 ), and HDL cholesterol (ρ = −0.35; p adj = 1.6 × 10 −2 ). Gamma-glutamyltyrosine is produced by the enzyme gamma-glutamyl transferase (GGT), a known biomarker of diabetes risk independent of body mass index (BMI) 27, 28 . We carried out an ordinary least-squares (OLS) regression with homeostatic risk assessment (HOMA-IR, a common marker for insulin resistance), as the dependent variable and GGT, gamma-glutamyltyrosine, age, sex, and BMI as the regressors (R 2 adj = 0.46) (Supplementary Table 7 ). In this model, gamma-glutamyltyrosine has a more significant effect on HOMA-IR (P = 4.3 × 10 −6 ) than does GGT (P = 0.09). If this finding is confirmed in a larger number of unrelated samples, gamma-glutamyltyrosine could be a candidate biomarker for diabetes risk independent of BMI.
Delta correlation network identifies changes over time Thirty-three communities of at least two vertices (mean of 24.9 V and 59.2 E) were identified in the inter-omic delta correlation network at the cutoff with maximum community modularity 12 Dataset 2) . 81% of the edges in the delta network remained after community edge pruning. This network contains many interesting relationships not found in the cross-sectional network. For example, changes in HDL cholesterol were positively correlated with changes in galanin (ρ = 0.36; p adj = 4.8 × 10 −3 ), a neuropeptide hormone with many physiological functions, including therapeutic associations with diabetes and Alzheimer's disease 29 . One of the delta communities (V = 15; E = 28) involved the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid (DHA), as well as the clinical analyte omega-3 index. Also present in this delta community is the furan fatty acid metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF). CMPF is elevated in the plasma of type 2 diabetes patients and directly implicated in beta cell dysfunction 30 , and has previously been observed to increase in response to omega-3 fatty acid supplements in diabetic patients 31 .
(Supplementary
Polygenic scores correlate with disease-risk analytes Several edges in the cross-sectional network represented correlations between genetic traits and corresponding biomarkers already identified in published studies. For example, blood levels of dihomo-γ-linolenic acid (DGLA) in our study were strongly correlated (ρ = 0.52; p adj = 1.8 × 10 −4 ) with a polygenic score computed from genotypes in six variants that were previously associated with DGLA levels 32 ( Fig. 5a) . We observed similar results for other omega-6 fatty acids including arachidonic acid, linoleic acid, and eicosadienoic acid as well as bilirubin, a marker of liver dysfunction (ρ = 0.52; p adj = 2.3 × 10 −4 ) 33 (Fig. 5b) . All tested associations with quantitative traits are presented in Supplementary Table 8 .
Although GWAS studies that model quantitative traits are most directly applicable to the measurements made in our study, other edges in the network occurred between polygenic disease risk and specific analytes. For example, the genetic risk of inflammatory bowel disease (IBD) in Europeans has been associated with 110 single-nucleotide polymorphisms (SNPs) 26 . In our cohort, the polygenic score for IBD calculated from all 110 SNPs was significantly negatively correlated with plasma cystine, the disulfide form of cysteine (ρ = -0.46; p adj = 7.4 × 10 −3 ) (Figs. 4d and 5c) .
We computed a bladder cancer polygenic score for all of our participants from nine SNPs previously associated with bladder cancer in a European cohort 34 . We identified an edge between this polygenic bladder cancer score and plasma levels of 5-acetylamino-6-formylamino-3-methyluracil (AFMU), an acetylated metabolite of caffeine, in our cohort. (ρ = 0.43; p adj = 1.9 × 10 −2 ). One variant is located downstream of NAT2, which encodes the enzyme N-acetyltransferase-2 responsible for acetylating carcinogenic compounds in urine. Polymorphisms in NAT2 are known to produce 'fast' and 'slow' acetylator phenotypes, of which the latter conveys higher risk for bladder cancer 35 (Figs. 4e and 5d ).
Coaching and biomarker improvements
In order to help participants modify their behavior and potentially improve their health throughout the 9-month period of this study, a behavioral coach talked participants through actionable possibilities from their data. Each month the coach worked with the participants and made recommendations for lifestyle changes with the aim of altering markers of known clinical significance and/or compensating for genetic predispositions ( Fig. 1 and Supplementary Fig. 3 ). Specific coaching recommendations based on personal data were customized by the coach, in consultation with the study physician. Specifically, for each measurement in an individual that was outside the clinical reference range (out-of-range) recommended by the clinical laboratory, the coach would recommend lifestyle changes that have been previously demonstrated to produce improvements in that marker. In making personalized recommendations, the coach used evidence-based behavioral approaches tailored to the participant's preferences and behavioral skill level. For example, for individuals Table  1 and Supplementary Table 10 . The most significant improvements for those who began the study out of range were observed in vitamin D (+7.2 ng/mL/round), mercury (−0.002 mcg/g/round), and HbA1c (−0.085%/round). We observed consistent improvements in total cholesterol measured by both Quest and Genova (−6.4 mg/dL/ round and −5.4 mg/dL/round, respectively). LDL cholesterol, measured only with Genova, significantly decreased (−4.8 mg/dL/round), while HDL cholesterol significantly increased (+4.5 mg/dL/round). Other significant improvements were observed in other diabetes risk factors (fasting insulin and HOMA-IR), and inflammation (IL-8 and TNF-alpha). Lipoprotein fractionation, performed by both laboratory companies, produced significant but discordant results for LDL particle number. We observed significant improvements in fasting glucose with Quest and concordant but non-significant improvements in fasting glucose with Genova. During the introductory coaching call one participant, a 65-yearold male, reported decreased mobility during hiking trips with his family and that his primary care physician had identified cartilage damage in his ankle. The baseline blood collection revealed that he had ferritin levels of 399 ng/mL, above the clinical reference range, and subsequent genetic analysis by our clinical team revealed he was homozygous for HFE C282Y, the primary genetic risk factor for hereditary hemochromatosis. Given his reported ferritin levels and genetic risk factors, our clinical team referred him to a hematologist, who diagnosed hemochromatosis and prescribed therapeutic phlebotomy. At the next blood draw, ferritin levels had dropped to 175 ng/mL and remained normal throughout the remainder of the study (Supplementary Fig. 4) . Hemochromatosis leads to excessive accumulation of dietary iron in various tissues and can be associated with serious complications later in life, including cartilage damage, liver disease, diabetes, and cardiac decompensation. After diagnosis, Generalized estimating equations (GEE) were used to calculate average changes in clinical laboratory tests over time, for those analytes that were actively coached on. The '∆ per round' column is the average change in the population for that analyte by round adjusted for age, sex, and self-reported ancestry. 'Out-of-range at baseline' indicates the average change using only those participants who were out-of-range for that analyte at the beginning of the study. Rows in boldface indicate statistically significant improvement, while the italicized row indicates statistically significant worsening. N/A values are present where no participants were out-of-range at baseline. For example, the average improvement in vitamin D for the 95 participants that began the study out-of-range was +7.2 ng/mL per round. Several analytes are measured by both Quest and Genova; with the exception of LDL particle number, the direction of effect for significantly changed analytes was concordant across the two laboratories. An independence working correlation structure was used in the GEE. See Supplementary A r t i c l e s this individual's primary care physician attributed his cartilage damage to early symptoms of hemochromatosis. Six other males had high ferritin levels but neither of the common genetic risk factors; four of the six were of Asian ancestry, out of only six male Asians in our study. It has previously been observed that Asians and Pacific Islanders have the highest mean population levels of ferritin despite a very low prevalence of risk factors for hemochromatosis 37 . These individuals were referred to their physicians for monitoring.
DISCUSSION
We report here the main findings from the P100 Wellness Project. We computed thousands of statistically significant inter-omic correlations using personal, dense, dynamic data clouds to identify many associations that could be followed up with perturbation experiments. We partitioned the correlations into data communities, which placed biomarkers in context within biological networks. This in turn led to the identification of putative biomarkers such as gamma-glutamyltyrosine, which was highly interconnected with clinical analytes for cardiometabolic disease. We identified molecular correlates of polygenic disease risk scores computed from published GWAS data, revealing possible ways in which genetic predisposition is manifested through analyte changes. Finally, the clinical biomarkers of many participants significantly changed in a healthy direction (Table 1 and  Supplementary Table 10 ) during the course of the study (e.g., type 2 diabetes and cardiovascular risk factors). Together these findings show that personal, dense, dynamic data clouds embody the essence of precision medicine 3 and present possibilities for the discovery of important medical applications. Data integration generated 3,470 significant (p adj < 0.05) crosssectional correlations and 2,406 significant delta (change over time) correlations after multiple hypothesis correction. Two known correlations indicate the potential existence of therapeutically valuable relationships. First, our analysis identified FGF21 as a potential contributor to cardiometabolic health. Indeed, obese diabetic patients treated with an FGF21 analog have shown improvements in triglycerides and other cardiovascular markers 38 . Second, l-thyroxine, through a negative correlation, was placed in a data community with cholesterol markers; supplementation with l-thyroxine lowered total cholesterol and LDL-C levels in patients with hypothyroidism in a clinical trial 39 . These two examples were identified from our data in an unsupervised manner.
We detected gamma-glutamyltyrosine, a metabolite of the enzyme biomarker gamma-glutamyl transferase (GGT). GGT is a clinical biomarker for liver disease, diabetes 27, 28 , and cardiovascular disease risk 40 . GGT catalyzes the transfer of the gamma-glutamyl moiety of glutathione to a substrate, commonly another amino acid, producing gamma-glutamyl dipeptides 41 . One of these dipeptides, gammaglutamyltyrosine, is highly interconnected within the cardiometabolic community and is a better predictor of HOMA-IR (insulin resistance) than GGT. Gamma-glutamyltyrosine might be a useful diagnostic marker for diabetes risk if our findings are replicated in an unrelated larger cohort. In clinical studies gamma-glutamyl dipeptides also discriminate different forms of liver disease 42 and predict 28-day mortality in intensive care unit patients 43 .
We identified correlations between calculated polygenic scores derived from common GWAS variants and measured analytes. For several studies (Supplementary Table 8 ) we were able to independently validate the cumulative associations of these variants with the expected quantitative trait (e.g., DGLA, LDL cholesterol, and bilirubin).
The polygenic score for IBD was significantly negatively correlated with levels of cystine in plasma samples of our cohort. A case-control study of IBD patients with either Crohn's disease or ulcerative colitis reported that plasma cystine and cysteine levels were abnormally low in affected individuals relative to controls, with the effect increasing with disease severity 44 . Decreased availability of the limiting substrate cystine suggests an impairment of glutathione synthesis in the intestine. Glutathione is an important intracellular antioxidant that is depleted in IBD inflammatory episodes, leading to excess reactive oxygen species and subsequent colonic inflammation and oxidative damage. Although Sido et al. 44 discuss cystine deficiency as an effect rather than a cause of IBD, our preliminary data suggest that lower levels of blood cystine may be more common in individuals at higher genetic risk for IBD before the disease manifests itself.
Specific genetic variants can be used to explain metabolite profiles using targeted variant-pathway interactions 45 . Our data suggest that GWAS polygenic scores can identify analyte associations with disease risk in a non-targeted manner (e.g., AFMU versus bladder cancer) and in the absence of direct associations between GWAS loci and plausible metabolic pathways (e.g., cystine vs. IBD). It is possible that supplementation with cystine in healthy individuals with high IBD genetic risk could prevent long-term low-grade inflammation and oxidative damage and thereby stop the wellness-to-disease transition to IBD. This hypothesis requires validation in follow-up experiments.
Most (89%) of our study participants were of European ancestry, and most (87%) of the 127 GWAS used as features for the correlation network were determined using European-ancestry populations (Supplementary Table 1 ). Principal component analysis plots of the population distribution of the P100 participants are shown in Supplementary Figures 5 and 6 . We are now evaluating approaches to control for ancestry of individuals in the computation of polygenic scores. This study was constrained to a small population of individuals living primarily in Seattle and northern California, but as we expand to other geographic areas our population diversity will increase.
We provided activity trackers (Fitbits) to our participants with the goal of measuring activity and sleep, but observed only modest compliance. We required a minimum of 40 days of Fitbit usage to estimate the average activity for each participant; 64% of the participants met this criterion. We included mean activity calories as a feature in our correlation network, but did not observe any statistically significant correlations with this feature. We observed even lower compliance with sleep tracking.
We developed an internal pipeline and curation protocol based on the American College of Medical Genetics and Genomics (ACMG) recommendations for reporting incidental findings in disease-associated genes (Online Methods). Three individuals were identified with previously annotated pathogenic or likely pathogenic variants. Our clinical team contacted each individual directly and securely provided them with a custom genetic report to take to their physician, along with a recommendation for follow-up clinical sequencing to confirm or disprove the incidental finding.
The opportunities for observing health transitions in a cohort of 108 individuals over 9 months are limited. We are now extending this pilot program with the aim of recruiting a large population 46 of more than 100,000 individuals by 2020.
Our study has the following limitations. The study design was not randomized in that none of the participants were denied wellness coaching or access to personal data.
We considered potential confounding from seasonality in the vitamin D improvements reported in Table 1 and Supplementary Table 10 . The improvements we observed in vitamin D levels (and attribute to supplementation) were considerably higher than would be expected based on seasonal changes in sun exposure 47 . Furthermore, we collected A r t i c l e s information on vitamin D dosage and report dose-dependent effects of supplementation (Supplementary Fig. 7) . We conclude that seasonality is a relatively minor confounding factor. Even after stringent multiple hypothesis correction, false discoveries are statistically inevitable. However, our approach could inform major efforts to translate omics-based data and build a learning healthcare system, as recently advocated by the US National Academy of Medicine 48 .
We hope that analyses of personal, dense, dynamic data clouds for a much larger cohort will enable the identification of network perturbations that result in common diseases, the design of diagnostics to detect early disease transitions, and the development of drugs and other interventions to reverse disease at the earliest stages. Personal, dense, dynamic data clouds are the essence of what precision medicine should be.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ONLINE METhODS
Approval for the study. Procedures for the P100 were run under the Western Institutional Review Board (IRB Protocol Number 20121979) at the Institute for Systems Biology (ISB). The study ran April 2014 to January 2015.
Recruitment of participants. Individuals in Washington state and California
were informally identified as interested in the P100 via personal communication and social networks of the authors. These individuals were then sent a formal e-mail announcement of the study from L.H. with an invitation to join. All 108 participants gave written informed consent for analysis of their data. Supplementary Figure 3 is a flowchart of recruitment/dropout and other events in the P100.
Analysis plan. At three time points throughout the study blood and urine samples from each participant were collected and processed using the procedures outlined by Genova Diagnostics and Quest Diagnostics and couriered to the testing facilities to maintain maximum sample stability.
Additional whole blood and plasma samples were collected from participants and shipped to BioStorage Technologies, an international CAP-accredited biorepository. Additional samples were used for metabolomics (Metabolon), SRM proteomics (ISB), Proseek Multiplex protein panels (Olink), and whole genome sequencing (Complete Genomics and the New York Genome Center). Participants collected stool samples at home for 16S rRNA sequencing (Second Genome), and were asked to provide daily activity and sleep data using personal monitoring devices (Fitbit).
Participants were asked to fast for 12 h before all blood collections. We observed a 99.3% compliance rate in fasting. Participants were asked by the phlebotomist to confirm compliance with the 12-h fast before each blood draw, and this was recorded on the requisition document. The P100 project manager sent out reminder e-mails before each blood draw period ('round') with instructions on how long to fast. Our clinical team reviewed the clinical data from each blood draw before its use in coaching.
Data were used throughout the study for coaching. Results presented in this report were analyzed at the end of the 9-month study using uniform standardized bioinformatics pipelines. All raw data collected as part of the P100 are available from dbGaP with accession ID phs001363.v1.p1.
Clinical laboratory tests.
For Genova, a total of one urine tube and nine blood tubes were collected. The blood tubes consisted of two Na-Heparin Trace Element tubes, three Serum Separator Tubes (SST), three EDTA purple top tubes, and one NMR black-top LipoTube. First morning void urine was collected in the Genova-provided green-top tube by participants the morning of their blood draw. Urine was sent frozen to Genova. Both Na-Heparin tubes were spun for 15 min at 3,000 r.p.m. The plasma from one Na-Heparin tube was transferred to a blue-top preservative tube provided by Genova and shaken and spun for 5 min at 2,500 r.p.m. Supernatant was then transferred to the yellow top transfer tube provided by Genova and shipped frozen. Plasma from the second Na-Heparin was transferred to an amber top transfer tube and shipped frozen. Each SST tube was left to clot for 15 min then spun for 15 min at 3,000 r.p.m. The plasma for all three was pipetted to transfer tubes and shipped frozen. All three EDTA-lavender top tubes were refrigerated after collection and shipped refrigerated. The single NMR black-top LipoTube was clotted for 30 min then spun for 15 min at 3,000 r.p.m. The specimen was left in the tube and shipped refrigerated.
Each saliva collection consisted of four samples within a single day (fourpoint cortisol test). For collection of the four saliva samples, participants were instructed to abstain from eating or drinking 30 min before each collection. All participants were given the following collection times for each of their four samples. Sample 1: collect before breakfast, between 7 a.m. Two SST tubes were collected for Quest Diagnostics. After collection the two tubes were left to clot for 15 min and then spun for 15 min at 3,000 r.p.m. Samples were left in the tube and shipped at ambient temperature.
All clinical laboratory tests measured using Quest and Genova are listed in Supplementary Gut microbiome 16S rRNA sequencing. Gut microbiome data in the form of 16S OTU (Operational Taxonomic Unit) read counts were provided by Second Genome. 250 bp paired-end MiSeq profiling of the 16S v4 region was performed as described previously 51 , with 50,000-150,000 reads generated per sample. 16S sequence clustering and open reference OTU picking 52 were performed using USEARCH with a proprietary strain database. Each OTU was then represented as a fraction of an individual's total microbiome composition. These OTU proportions were placed in a vendor-provided taxonomy and aggregated at the kingdom, phylum, class, order, family, genus, and species levels (Supplementary Tables 1 and 12 ). α-diversity 53 , a measure of the number of OTUs observed as well as the evenness of their distributions, was calculated as the within-sample Shannon diversity index:
where p ij is the relative abundance of OTU i in sample j.
Second Genome performed our microbiome OTU picking using their proprietary strain database. Many microbiome studies are performed using OTU picking against the publicly available Greengenes database, but Second Genome recommended that we use their curated database. Their database is specifically customized for microbes that exist in the human gut, whereas the Greengenes database spans a broad range of microbes, for example, soil and water microbes and those found in other organisms. The proprietary strain database used for microbiome analyses can be downloaded using the following URL: http://secondgenome.com/solutions/resources/data-analysistools/strain-select/.
We used β-diversity to assess the degree to which each participant's microbiome composition resembled itself over time (Supplementary Fig. 8 ). In nearly all cases, individuals' microbiome composition was more similar to their previous sample than to other individuals' . For these inter-individual comparisons, representative sequences were aligned using PyNAST 1.2.2 (ref. 54) via QIIME 1.9.1 (ref. 55 ) with the Greengenes 56 85% OTU representative sequences as a template. The alignment was filtered to remove high entropy positions using the Lane mask 57 . A phylogeny was reconstructed using FastTree 2.1.7. Unweighted UniFrac distances [58] [59] [60] were computed on the table using QIIME. scikit-bio 0.2.3 (http://scikit-bio.org) was used in a custom Jupyter Notebook 61 with matplotlib 62 and seaborn to process the distance matrix. Specifically, for each sample, the distance between it and the participant′s successive time point was determined (the red points in Supplementary Fig. 8 ). All the distances from that sample to all other samples at the successive time point were then retrieved (the box-whisker plots in Supplementary Fig. 8 ). Subsequent statistics were computed using SciPy 0.17.0.
Metabolomics. Metabolon Inc. conducted the metabolomics assays on participant plasma samples at three time points for each participant throughout the course of the study. Metabolon Inc. generated the data using their DiscoveryHD4 platform in addition to their Fatty Acid Metabolism (FAME) panel that uses a combination of ultra-high-performance liquid chromatography with tandem mass spectrometry (MS) and gas chromatography (GC) in the identification of metabolites and fatty acids. The metabolite values were reported relative to their concentrations among all participants, except for lipids that were measured via GC-FID, which were reported as molar percentages of each participant's total fatty acids. For analysis, the metabolomics data were median-scaled, such that the median value for each metabolite was one, and values that fell beneath the range of detection were imputed to be the minimum observed value. This scaling was performed across all samples. All time points were run as a single batch. Counts of metabolites detected using each technology are listed in Supplementary Olink proximity extension assays. Protein levels in plasma were determined by Proximity Extension Assays (PEA) using two Olink (Uppsala, Sweden) Proseek Multiplex 96 × 96 kits and quantified by real-time PCR using the Fluidigm (South San Francisco, California) BioMark HD system. Each kit provides a microtiter plate for measuring 92 protein biomarkers in 90 samples. Each well contains 96 pairs of DNA-labeled antibody probes. When a matched pair of probes bind to their target protein, their DNA labels are brought into close proximity and a PCR target sequence is formed by a proximity-dependent DNA polymerization. One plate contains 96 wells for processing 90 samples, 3 positive controls, and 3 negative controls to determine the lower detection limit. Each sample is also spiked with four controls to monitor variation in the three steps of the PEA process. Two non-human antigens serve as incubation controls, one DNA-labeled antibody serves as an extension control, and an oligonucleotide serves as a detection control.
The Proseek cardiovascular (CVD I) and inflammation (Inflammation I) panels target 158 different proteins with 19 overlapping measurements. Plasma samples from 80 subjects drawn at three intervals were assayed. One sample was assayed in triplicate on all plates and additional samples were replicated for a total of 270 multiplex cardiovascular and 270 multiplex inflammation assays. A total of 41,085 data points were collected. Assays were run according to the manufacturer's instructions. In short, 1 µl of each sample was incubated with the antibody probes at 4 °C overnight. After binding, the extension mix was added and the products were extended and amplified using 17 cycles of PCR (Applied Biosystems 9700, Life Technologies, Carlsbad, California). Next, 2.8 µl of each PCR product was added to the detection mix and loaded into the sample wells of a Fluidigm 96.96 Dynamic Array plate (Fluidigm Corporation) while kit primers were loaded into the primer wells. The Dynamic Array was primed in a Fluidigm HX IFC controller and then loaded into the Fluidigm BioMark imaging thermocycler for quantitative PCR. Quantification cycle (Cq) values for each measurement were determined using Fluidigm′s RealTime PCR Analysis software and BiomarkDataCollection version 4.1.3. Data were normalized using the extension positive control and the negative control Cq values. The limit of detection was defined as three times the s.d. of the negative controls. See Supplementary Table 1 for all proteins detected using Olink proximity extension assays.
Selected reaction monitoring (SRM) analysis. SRM assay and method development. SRM assays were developed for 200 peptides representing 100 proteins. See Supplementary Table 1 for all SRM peptides. For each peptide sequence the heavy-isotope-labeled analog was synthesized (PEPotec SRM library Grade 1, Thermo-Fisher Scientific, Huntsville, AL) with cysteine residues carbamidomethylated and the C-terminal arginine as R[13C6, 15N4] or lysine as K[13C6, 15N2] to allow for relative quantification. The 200 synthetic peptides were individually analyzed on a 6530 accurate-mass Q-TOF liquid chromatography mass spectrometry (LC-MS) system (Agilent Technologies, Santa Clara, CA) using a ProtID-Chip-150 (II) (Agilent Technologies, Santa Clara, CA) to verify and confirm successful peptide synthesis. The 200 peptides were pooled as internal standard. Multiplexed SRM assays were established with the human SRMAtlas 63 (www.srmatlas.org) and the synthetic peptides on a 6460 QQQ MS system equipped with Jet Stream ESI technology and a 1290 Series UHPLC (Agilent Technologies, Santa Clara, CA). SRM assays were optimized with regard to sensitivity and specificity, and with the aim to target 200 peptides in a single analysis. 1,200 transitions were determined, 3 transitions to target each light endogenous peptide and 3 transitions to target each isotope-labeled heavy peptide, and peptides separated on a reversed phase column (Zorbax SB-C18, 50 mm × 2.1 mm I.D., 1.8 µm dp, Agilent Technologies, Santa Clara, CA) using a gradient from 3% to 30.5% acetonitrile/0.1% formic acid/water over 55 min at a flow rate of 0.2 mL/min. Data were acquired in dynamic MRM mode with a fixed cycle time of 2,500 ms and a minimum dwell time of 10 ms.
Plasma sample preparation. Plasma samples were thawed on ice and centrifuged for 10 min at 14,000 r.p.m. to separate tissue debris or a lipid layer. 110 µL plasma were depleted from the 14 most abundant plasma proteins using the multiple affinity removal system (MARS Hu-14, 4.6 × 100 mm, Agilent Technologies, Santa Clara, CA) according to the manufacturer's protocol. The depleted fraction was collected in 1.25 mL of MARS14 Buffer A and denatured by adding 600 mg urea to 8 M final concentration. Samples were reduced with 5 mM dithiothreitol for 30 min at 55 °C, alkylated with 14 mM iodoacetamide for 30 min at room temperature in darkness and desalted using a GE HiPrep 26/10 column (GE HealthCare Life Sciences, Pittsburgh, PA) and 1200 HPLC system (Agilent Technologies, Santa Clara, CA). The protein concentration of the desalted samples was determined by bicinchoninic acid assay (BCA) (Thermo-Fisher Scientific, San Jose, CA). An aliquot of the pooled 200 synthetic peptides was spiked into an aliquot of each plasma sample (equal protein amounts) before the digestions with trypsin (Promega, Madison, WI) at 1:50 enzyme:substrate ratio for 16 h at 37 °C. Digests were dried under centrifugal vacuum evaporation (Savant, Thermo-Fisher Scientific, San Jose, CA) and reconstituted to 1 µg/µL protein concentration.
Plasma sample analysis. 20 µg of each plasma sample spiked with the 200 isotope-labeled peptides was subjected to SRM analysis using the method described above. SRM data were analyzed with Skyline 64 . SRM traces were integrated with default settings and manually inspected to verify correct peak assignment and co-elution of endogenous and isotope-labeled standard peptides. The relative peptide abundance level was reported as ratio of endogenous light to the heavy standard.
Quantified self-tracking. Participants were asked to wear a Fitbit activity tracker throughout the 9-month study. Participants were offered either a Fitbit Flex (wrist) or a Fitbit One (clip-on). These Fitbit models measure activity using the number of steps an individual takes each day. The models available at the time of the study did not measure heart rate, as current models do, resulting in inconsistent activity measurements for, for example, running versus cycling. Furthermore, the devices required manual entry and exit of 'sleep mode' for sleep tracking, for which compliance was too low to provide useful data. We required a minimum of 40 days of Fitbit usage in order to estimate the average activity for each participant; 64% of the participants met this criterion. The Fitbit device estimates user-specific 'activity calories' independently of basal metabolic rate (BMR). For all calculations, we used only the estimated 'activity calories' , excluding BMR. We used these data only as a relative indicator of activity levels rather than an absolute measure of caloric burn.
Genomic traits. The National Human Genome Research Institute's GWAS catalog lists results from more than 2,000 published studies comprising over 1,000 genetic traits 9 . We applied a strict filtering procedure to identify GWAS used for this study. First, we excluded studies which did not contain at least one SNP with P < 1.0 × 10 −8 . Studies which contain few SNPs are likely to produce a vector of cumulative genetic variation with low entropy, where almost all values are identical save a few. Such low entropy measurements are more likely to produce spurious correlations in our relatively small number of samples. We therefore excluded all traits associated with five or fewer SNPs. Furthermore, we required studies to have a sample size of at least 5,000 individuals. In the event that multiple studies examined the same trait, we kept the study with the largest sample size. Finally, we manually excluded traits with too-generic descriptions (e.g., 'common traits' or 'metabolic traits'), which did not provide a useful description of the purpose of the original study. The combination of these filters retained 127 genetic traits that we used for further analysis. Three common copy number variations (CNVs) were included as additional genetic features computed using Reference Coverage Profiles 49 , bringing the total to 130. See Supplementary Table 1 for all genetic traits computed for this manuscript.
Included in the GWAS catalog are the beta-coefficients/odds ratios as well as the P-values for the predicted effect of each variant for that trait based on the association models from the original paper. We made two assumptions to simplify the calculation of the polygenic scores. First, we assumed that the beta-coefficients (or log odds ratios) combined in an additive manner based on the number of effect alleles present in each individual. Therefore, if a single effect allele was present we added the beta-coefficient or log odds ratio for that variant into the cumulative polygenic score. If two copies of the effect allele were present we added twice the value of the beta-coefficient or log odds ratio into the cumulative genetic effect for that individual. The second assumption was that the effects of each variant are independent of the effects of all other variants used in the model. These two simplifying assumptions allowed us to calculate the polygenic score for each trait across each individual in our study.
There are a number of pitfalls to this approach that served to temper our expectations. First, GWAS only identify variants that occur commonly enough in the population to be associated statistically with a trait. Unless one is able to genotype a substantial fraction of the human population at risk for a particular trait, rare variants will never rise above the level of noise in a GWAS. Furthermore, because they employ genotyping chips most GWAS ignore CNVs or structural variations (SVs) that may have a significant effect on genetic traits. We included as part of our study three common CNVs as additional genomic features. Finally, many GWAS are applied to cohorts of individuals from similar ancestries to improve their likelihood of discovering associated variants; it is therefore possible that results from these studies do not generalize to individuals from differing ancestral populations.
There are other analysis options available for WGS data that would be appropriate for subsequent studies with an 'N of 1' focus. For example, one could perform rare or de novo variant analysis, which identify genetic variants that are either very rare in the population or unique to an individual, respectively. GWAS focus on variants which are common enough in the population to find significant associations with quantitative traits or diseases. The interpretation of rare and de novo variants can be difficult, as each variant must be interpreted in the context of functional impact. Sequencing and phenotyping relatives (e.g., family-based analysis) is a method to assist in interpreting the functional impact of de novo variants. Another possible analysis technique for WGS data is burden analysis, which calculates a cumulative burden score on each gene and attempts to associate these scores with phenotypes.
Coaching, charting, and compliance tracking. The P100 was designed as a prospective study that attempted to help participants modify their behavior to enhance their health throughout the 9-month period. Participants were assigned to a behavioral coach, who walked them through actionable possibilities from their data and made recommendations on lifestyle changes. These lifestyle changes were recommended in an attempt to alter markers of known clinical significance and/or compensate for genetic predispositions for which reliable published evidence is available. Each participant was eligible for one 30-min coaching session per month, though participants were not penalized or excluded from the study if they chose not to participate in the coaching sessions. Participants were also able to communicate privately and securely with the coach via a website portal created specifically for this project. Participants also received their data through the website portal. The P100 collected statistics on participation in the coaching calls and compliance with sample collection.
As previously stated, clients were offered specific coaching recommendations based on their genetics and clinically actionable data. These recommendations were customized before each call by the study clinician and coach, in consultation with the study physician. All clinical markers and recommendations were reviewed and approved by the study physician before their communication to each participant. While these recommendations were specific to each individual based on their data, they typically fell into one of several major categories, including diet, exercise, stress management, dietary supplements, or physician referral. Coaching focused on four primary health areas: cardiovascular, diabetes, inflammation, and nutrition. The clinical tests that were actively coached on are provided in Supplementary Action items were recorded in each participant's chart by our behavioral coach during each coaching call. These charts were used to keep participants on track and follow standard clinical practice guidelines. Post-study we reviewed each de-identified chart in detail with our behavioral coach to extract compliance data for each recommendation. We learned a great deal about how to merge standard clinical practice (e.g., charting in free-text fields, as practiced by clinicians) with the need for automated database storage of predefined and enumerated recommendations. Subsequent studies will investigate specific effects of recommendations and compliance on clinical data as well as other omics data with far larger N.
Data preprocessing. Each data set was transformed into comparable data vectors for statistical analysis. All measurements were mean-centered and scaled by the standard deviation of the observed measurements. The microbiome measurements were compared independently at the phylum, class, order, and family taxonomic levels. With the exception of the median-scaled metabolomics data, missing data were not imputed; participants that had a missing value were dropped from pairwise comparisons using that value. Each analyte was age-and/or sex-corrected if a trimmed mean robust regression identified a significant relationship (P < 0.01, unadjusted) between age and/or sex and the dependent variable. Age and sex corrections were performed independently, so it was possible for an analyte to be age corrected but not sex corrected, and vice versa. If an analyte was corrected the residuals of the model were used in place of the original observations. If no corrections were made, the original mean-centered and scaled measurements were used. See Supplementary Table  14 for statistics on age and sex correction.
Correlation network and community analysis. We created two different types of correlation networks: 'cross-sectional' and 'delta' correlations. Cross-sectional correlations were calculated from mean measurements of analytes calculated across all rounds (i.e., mean A is correlated with mean B across all individuals). Delta correlations were calculated on the change in analytes between rounds (i.e. the change in A for an individual between time points is correlated with the change in B, where the correlation is again calculated across all individuals). We used each pair of adjacent time points (r 2 -r 1 ) and (r 3 -r 2 ) to build the delta correlation network, where all such comparisons were used in the two vectors that were being compared. Therefore, each individual with three observations is represented twice for each calculated delta correlation. For example, while the cross-sectional correlation network was created by correlating vectors of maximum length N = 108, the delta correlation network was created by correlating vectors of maximum length N = 216. Our reasoning is that each pair of adjacent time points is an independent observation of a potential correlation in time, even though they are not drawn from a completely independent set of individuals. For each pairwise set of data (e.g., clinical tests versus proteomics, clinical tests versus metabolomics, etc.), each measurement from the first data set was correlated with every measurement from the second data set using Spearman's ρ. P-values were adjusted for multiple hypothesis testing using the method of Benjamini and Hochberg 10 ; we chose an adjusted Pvalue (p adj ) cutoff of 0.05 as our significance level. Only inter-omic correlations were used for community analysis. Both inter-omic and intra-omic (e.g., metabolomics versus metabolomics) cross-sectional and delta correlations are reported in Supplementary Tables 2-5 and visualized in Figure 2 and Supplementary Figure 1 . We assessed reproducibility of duplicate measurements across two clinical laboratories ( Supplementary  Fig. 9 ). As correlations between repeat measurements do not represent physiologically relevant information, they are not included in our network or subsequent analysis. We note the poor correlation between LDL particle number measured with both Genova and Quest as an explanation for the discordant laboratory results for this analyte reported in Table 1 and  Supplementary Table 10 .
We performed community analysis using the method of Girvan and Newman 11 . This method involves iteratively calculating edge betweenness centrality on a network: the number of weighted shortest paths from all vertices to all other vertices that pass over that edge. After each iteration, the edge(s) with the highest betweenness centrality were removed, and the process was repeated until only individual nodes remain. All communities can also be dynamically visualized in Cytoscape 13 ( Supplementary Datasets 1 and 2) .
Community analysis forms a dendrogram that can be analyzed at multiple hierarchical levels. For this manuscript we analyzed our network at a cut level determined using an unbiased method, the modularity of the community structure 12 . Briefly, modularity of community structure corresponds to an arrangement of edges that is statistically improbable when compared to an equivalent network with edges placed at random. At every iteration of the community analysis, we computed the modularity, and analyzed the communities at the iteration which maximized this quantity. A visualization of community modularity vs. iteration is shown in Supplementary Figure 2. OLS regression tests. To test for heteroscedasticity in our HOMA-IR regression model, we fit the model using White's heteroscedasticity-consistent estimator (HCE), and the results were consistent with those reported in the manuscript: gamma-glutamyltyrosine was still significantly more predictive (P = 2.3 × 10 −4 ) of HOMA-IR than GGT (P = 0.02). To test for the effects of outliers, we fit a robust regression model and again the results were consistent with those reported in the manuscript. To test for multicollinearity, we calculated the variance inflation factors (VIF) for each predictor. The maximum VIF was 1.7, indicating a low amount of correlation between the predictors of the model.
Statistical analyses.
All data types used in the cross-sectional and delta correlation networks were normalized as described in their respective method sections. Additionally, where we were able to identify a significant effect (P < 0.01, unadjusted) with age and/or sex using trimmed mean robust regression we used the residuals as the comparison value. These adjustments were performed independently for age and sex. We report the calculated P-values for age and sex with every variable, as well as whether the variable was age and/or sex adjusted in Supplementary Table 14. All transformations were performed with the Python Statsmodels package (v0.6) with robust linear models using the trimmed mean norm. Unadjusted analytes were compared using the original mean-centered and scaled measurements.
We created two different types of correlation networks: 'cross-sectional' and 'delta' correlations. Cross-sectional correlations were calculated from mean measurements of analytes calculated across all rounds (i.e., mean A is correlated with mean B across all individuals). Delta correlations were calculated on the change in analytes between rounds (i.e., the change in A for an individual between time points is correlated with the change in B, where the correlation is again calculated across all individuals). We used each pair of adjacent time points (r 2 -r 1 ) and (r 3 -r 2 ) to build the delta correlation network, where all such comparisons were used in the two vectors that were being compared. Therefore, each individual with three observations is represented twice for each calculated delta correlation. For example, while the cross-sectional correlation network was created by correlating vectors of maximum length N = 108, the delta correlation network was created by correlating vectors of maximum length N = 216. For each pairwise set of data (e.g., clinical tests versus proteomics, clinical tests versus metabolomics, etc.), each measurement from the first data set was correlated with every measurement from the second data set using Spearman's ρ. P-values were adjusted for multiple hypothesis testing using the method of Benjamini and Hochberg 10 ; we chose an adjusted P-value (p adj ) cutoff of 0.05 as our significance level. Only inter-omic correlations were used for community analysis.
We performed community analysis using the method of Girvan and Newman 11 . This method involves iteratively calculating edge betweenness centrality on a network: the number of weighted shortest paths from all vertices to all other vertices that pass over that edge. After each iteration, the edge(s) with the highest betweenness centrality were removed, and the process was repeated until only individual nodes remain.
For this manuscript we analyzed our network at a cut level determined using an unbiased method, the modularity of the community structure 12 .
At every iteration of the community analysis, we computed the modularity, and analyzed the communities at the iteration that maximized this quantity (Supplementary Fig. 2) .
OLS regression on the dependent variable HOMA-IR, with regressors including sex, GGT, gamma-glutamyltyrosine, age, and body mass index was performed (Supplementary Table 7) . To test for heteroscedasticity in our HOMA-IR regression model, we fit the model using White's heteroscedasticity-consistent estimator (HCE), testing for the effects of outliers using a robust regression model and testing for multicollinearity by calculating the variance inflation factors (VIF) for each predictor.
Generalized estimating equations (GEE) were used to calculate the average change in each clinical analyte by round while controlling for the effects of age, sex, and self-reported ancestry ( Table 1 and Supplementary Table 10 ). An independence working correlation structure was used in the GEE.
Software packages. NYGC used BWA v0.7.8-r455 to align sequences. Complete Genomics CGAPipeline v2.5.0.20. NYGC provided a VCF4.1 file for each sequenced sample calculated with GATK HaplotypeCaller, following duplicate marking with Picard v1.83, and indel realignment and base quality recalibration. GATK v3.1.1-g07a4bf8 was used for BAM file post-processing and variant calling. Copy number variant status was determined using Reference Coverage Profiles 49 . Variant frequencies were annotated using Kaviar 50 .
OTU picking for the microbiome results used for the correlation networks was performed using USEARCH with a proprietary strain database, which can be downloaded at: http://secondgenome.com/solutions/resources/dataanalysis-tools/strain-select/. Inter-individual microbiome comparisons were performed using PyNAST 1.2.2 (ref. 52) via QIIME 1.9.1 (ref. 55 ) with the Greengenes 56 85% OTU representative sequences as a template. The alignment was filtered to remove high entropy positions using the Lane mask 57 . A phylogeny was reconstructed using FastTree 2.1.7. Unweighted UniFrac distances [58] [59] [60] were computed on the table using QIIME. scikit-bio 0.2.3 (http://scikit-bio. org) was used in a custom Jupyter Notebook 61 with matplotlib 62 and seaborn to process the distance matrix.
Olink Cq values for each measurement were determined using Fluidigm′s Real-Time PCR Analysis software and BiomarkDataCollection version 4.1.3.
Multiplexed SRM assays were established with the human SRMAtlas 63 (www.srmatlas.org) and analyzed with Skyline 64 .
All pairwise statistical tests (Spearman) were performed using the Python scipy.stats package (v0.14). All regression models (OLS regressions and GEE) were fit using the Python Statsmodels package (v0.6) 65 . An independence working correlation structure was used for GEE. Variance inflation factors were calculated using Python Statsmodels (v0.6) package. Correlation network Pvalues were adjusted for multiple hypothesis using the Benjamini-Hochberg 10 method via the Python Statsmodels (v0.6) package for each inter-datatype comparison. Community analysis and modularity calculations were performed in Python with the NetworkX 66 package, the python-louvain package (v0.3), and custom code. All custom code used in this manuscript can be downloaded from Github using the link below and is also available as Supplementary Code. The Github version used for the manuscript is 'v-release' .
https://github.com/trueprint/p100-network-code/tree/v-release ACMG incidental finding reporting. Genes listed in the American College of Medical Genetics and Genomics (ACMG) recommendations for incidental findings 67 were tabulated along with associated reporting requirements (known pathogenic and expected pathogenic) and inheritance pattern (autosomal recessive, autosomal dominant, X-linked). The ClinVar database was obtained from the NCBI (ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/). Records from ClinVar were filtered to overlap with genes reported in the ACMG incidental finding list by gene symbol. The remaining records were further filtered to only include variants where at least one submitter indicated a variant was pathogenic or likely pathogenic, and no submitter indicated a variant was benign or likely benign (i.e., no conflicting interpretations of pathogenicity). P100 participants' VCF files were filtered for variant calls intersecting the chromosome and position of these filtered ClinVar records. Only calls with a FILTER value of PASS were included. If the record was a SNP, the alternate allele of each variant call was compared against the effect allele of the ClinVar record to ensure a match.
